K192773 is an FDA 510(k) clearance for the ALLIVE. Classified as Stimulator, Nerve, Electrical, Transcutaneous, For Migraine (product code PCC), Class II - Special Controls.
Submitted by Nu Eyne Co., Ltd. (Seoul, KR). The FDA issued a Cleared decision on December 6, 2019 after a review of 67 days - a notably fast clearance cycle.
This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.5891 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.
View all Nu Eyne Co., Ltd. devices